Mirtazapin Bluefish (Mirtazapine)

Mirtazapine is indicated for depressive disorders and works by modulating noradrenergic and serotonergic pathways.

• Major depressive disorder: reduces depressive symptoms and improves functional outcomes.
• Depressive episodes in major depressive disorder: alleviates mood disturbances and enhances sleep quality.
• Treatment‑resistant depression (adjunct use): may be considered when first‑line agents are insufficient.

• Mirtazapine antagonizes central presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine. It also blocks postsynaptic 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A, thereby enhancing serotonergic transmission. The combined effect raises both norepinephrine and serotonin levels in key brain regions involved in mood regulation.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Sedation or drowsiness.
• Increased appetite and weight gain.
• Dry mouth.
• Constipation.
• Dizziness.
• Orthostatic hypotension.

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia.
• Serotonin syndrome, especially with other serotonergic agents.
• Suicidal thoughts or behavior, particularly early in treatment.
• Severe hepatic injury.
• Hypersensitivity reactions such as rash or angioedema.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

• Monitor weight and metabolic parameters: mirtazapine can increase appetite and cause weight gain.
• Assess for suicidal ideation: especially during the first weeks of treatment.
• Use caution in hepatic impairment: dose adjustments may be required.
• Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms.
• Review concomitant CNS depressants: combined use may enhance sedation.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes; understanding the severity helps guide clinical decisions.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased serotonin toxicity.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels.
• Alcohol: enhances sedative effects and orthostatic hypotension.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: potential additive hypotensive effect.
• Anticholinergic medications: may increase anticholinergic burden.
• CYP3A4 inhibitors (e.g., ketoconazole): modest increase in exposure.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of gastrointestinal bleeding.
• Lithium: monitor serum lithium levels due to possible pharmacodynamic changes.